NEWS - Nov 8, 2023 Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results Read more
NEWS - Nov 3, 2023 Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023 Read more
NEWS - Oct 11, 2023 Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023 Read more
NEWS - Oct 9, 2023 Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit Read more
NEWS - Oct 6, 2023 Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress Read more
NEWS - Sep 20, 2023 Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder Read more
NEWS - Aug 23, 2023 Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder Read more
NEWS - Aug 8, 2023 Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results Read more
NEWS - Aug 1, 2023 Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023 Read more
